A Biospecimen and Clinical Data Study on Patients With Alzheimer's, Multiple Sclerosis, Parkinson's, and Huntington's, for Drug & Biomarker Discovery

Sponsor
Sanguine Biosciences (Industry)
Overall Status
Completed
CT.gov ID
NCT01592552
Collaborator
(none)
20
1
40
0.5

Study Details

Study Description

Brief Summary

The purpose of this research project is to collect and store blood samples and clinical data. Researchers can then use the stored samples in future studies. Through such studies, they hope to find new ways to detect, treat, and maybe even prevent or cure health problems.

Detailed Description

Blood samples are collected in the comfort and safety of your home by a certified medical professional. We have mobile phlebotomists located in major metropolitan areas around the nation for your convenience.

Study Design

Study Type:
Observational
Actual Enrollment :
20 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
A Multi-Center Longitudinal Biorepository Study to Provide Biospecimens & Clinical Data From Neurological Disease Patients To Approved Pre-Clinical And Clinical Investigators for Drug & Biomarker Studies
Study Start Date :
Nov 1, 2011
Actual Primary Completion Date :
Mar 1, 2015
Actual Study Completion Date :
Mar 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Neurological Condition

Collect blood and other biospecimens like saliva, urine and CSF for research purposes.

Control

Collect blood and other biospecimens like saliva, urine and CSF for research purposes.

Outcome Measures

Primary Outcome Measures

  1. Biospecimens & Clinical Data collection from patients with neurological diseases. [2 years]

    The purpose of this research project is to collect and store blood samples and clinical data. Researchers can then use the stored samples in future studies. Through such studies, they hope to find new ways to detect, treat, and maybe even prevent or cure health problems.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Males and females >18 to 100 years old

  • A diagnosis of neurological condition

  • Proof of diagnosis can be provided

Control group: Healthy donors, males and females, 18 to 100 years of age

Exclusion Criteria

  • Receipt of blood products within 30 days of study enrollment

  • Receipt of an investigational (unapproved) drug within 30 days of study enrollment

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sanguine Biosciences Sherman Oaks California United States 91403

Sponsors and Collaborators

  • Sanguine Biosciences

Investigators

  • Principal Investigator: Phil Silkoff, MD, Sanguine Biosciences

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sanguine Biosciences
ClinicalTrials.gov Identifier:
NCT01592552
Other Study ID Numbers:
  • SAN-ND-01
First Posted:
May 7, 2012
Last Update Posted:
Apr 8, 2019
Last Verified:
Apr 1, 2019

Study Results

No Results Posted as of Apr 8, 2019